patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_335505 | REC_0002601 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 23 | 15 | 74 | female | 1 | 18 | 7.5 | 1 | alectinib 600 mg BID | 23.9 | false | MSS | 2026-03-15T05:35:57.486004+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_503213 | REC_0002602 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 28 | 17.9 | 67 | female | 1 | 18 | 5.1 | 1 | sotorasib 960 mg daily | 9.9 | false | MSI-H | 2026-03-15T05:35:57.486237+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_651530 | REC_0002603 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 33 | 10.4 | 68 | female | 0 | 12 | 5.5 | 2 | osimertinib 80 mg daily | 22.9 | false | MSI-H | 2026-03-15T05:35:57.486475+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_739746 | REC_0002604 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 32 | 6.9 | 72 | female | 2 | 12 | 4.2 | 7 | entrectinib 600 mg daily | 9.7 | false | MSS | 2026-03-15T05:35:57.486704+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_995605 | REC_0002605 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 19 | 13.3 | 74 | male | 1 | 14 | 7.5 | 1 | alectinib 600 mg BID | 20.8 | true | MSS | 2026-03-15T05:35:57.486939+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_274837 | REC_0002606 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 27 | 13.7 | 71 | female | 2 | 19 | 4.4 | 1 | sotorasib 960 mg daily | 21 | false | MSS | 2026-03-15T05:35:57.487172+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_260568 | REC_0002607 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 32 | 10.1 | 64 | male | 0 | 13 | 7.1 | 4 | pembrolizumab 200 mg q3w | 12 | false | MSI-H | 2026-03-15T05:35:57.487407+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_159686 | REC_0002608 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 20 | 10.6 | 58 | female | 1 | 19 | 5.3 | 2 | entrectinib 600 mg daily | 12 | false | MSS | 2026-03-15T05:35:57.487642+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_173394 | REC_0002609 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 16 | 11.1 | 64 | male | 0 | 20 | 6 | 7 | osimertinib 80 mg daily | 9 | true | MSI-H | 2026-03-15T05:35:57.487877+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_493192 | REC_0002610 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 21 | 8.3 | 61 | male | 0 | 12 | 5.3 | 2 | sotorasib 960 mg daily | 16.6 | false | MSS | 2026-03-15T05:35:57.488149+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_535886 | REC_0002611 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 28 | 12.4 | 67 | female | 0 | 13 | 6.8 | 1 | pembrolizumab 200 mg q3w | 13.2 | false | MSI-H | 2026-03-15T05:35:57.488390+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_794171 | REC_0002612 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 24 | 5 | 67 | female | 1 | 26 | 4.5 | 2 | osimertinib 80 mg daily | 24 | true | MSS | 2026-03-15T05:35:57.488621+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_365938 | REC_0002613 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 20 | 5.8 | 67 | female | 0 | 21 | 8 | 2 | pembrolizumab 200 mg q3w | 12.9 | false | MSS | 2026-03-15T05:35:57.488853+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_452246 | REC_0002614 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 23 | 7.5 | 69 | female | 1 | 19 | 3.8 | 6 | sotorasib 960 mg daily | 8.6 | true | MSS | 2026-03-15T05:35:57.489126+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_881905 | REC_0002615 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 23 | 7.2 | 60 | female | 1 | 16 | 6.2 | 1 | osimertinib 80 mg daily | 13.1 | false | MSS | 2026-03-15T05:35:57.489364+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_770105 | REC_0002616 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 10.2 | 68 | female | 0 | 22 | 6.3 | 7 | sotorasib 960 mg daily | 10.5 | false | MSI-H | 2026-03-15T05:35:57.489596+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_723765 | REC_0002617 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 27 | 9.1 | 58 | female | 0 | 20 | 6.2 | 1 | alectinib 600 mg BID | 24.8 | true | MSS | 2026-03-15T05:35:57.489830+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_857756 | REC_0002618 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 17 | 6.8 | 63 | female | 1 | 9 | 3.6 | 1 | osimertinib 80 mg daily | 10 | true | MSS | 2026-03-15T05:35:57.490063+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_148278 | REC_0002619 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 22 | 14 | 62 | female | 1 | 20 | 4 | 1 | alectinib 600 mg BID | 10.4 | false | MSS | 2026-03-15T05:35:57.490299+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_333399 | REC_0002620 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 23 | 15 | 59 | female | 1 | 9 | 5.8 | 2 | alectinib 600 mg BID | 19.3 | true | MSS | 2026-03-15T05:35:57.490531+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_123739 | REC_0002621 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 33 | 15.3 | 56 | female | 1 | 13 | 4.3 | 2 | osimertinib 80 mg daily | 8.3 | false | MSI-H | 2026-03-15T05:35:57.490765+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_872956 | REC_0002622 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 25 | 14.6 | 82 | female | 2 | 13 | 7.2 | 5 | osimertinib 80 mg daily | 13.3 | false | MSI-H | 2026-03-15T05:35:57.490999+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_425501 | REC_0002623 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 30 | 10 | 66 | female | 1 | 16 | 5.1 | 4 | osimertinib 80 mg daily | 14 | true | MSS | 2026-03-15T05:35:57.491234+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_138335 | REC_0002624 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 26 | 14.7 | 61 | female | 0 | 18 | 6.4 | 1 | sotorasib 960 mg daily | 6 | false | MSI-H | 2026-03-15T05:35:57.491467+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_937049 | REC_0002625 | Non-small cell lung cancer | Squamous cell carcinoma | III | None | 22 | 6.8 | 71 | male | 2 | 34 | 2.8 | 0 | carboplatin + paclitaxel + pembrolizumab | 29.4 | true | MSS | 2026-03-15T05:35:57.491698+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_811586 | REC_0002626 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 26 | 11 | 76 | male | 3 | 16 | 5.1 | 8 | entrectinib 600 mg daily | 4 | false | MSI-H | 2026-03-15T05:35:57.491932+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_813447 | REC_0002627 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 23 | 12.9 | 66 | female | 0 | 0 | 3 | 4 | entrectinib 600 mg daily | 6.1 | false | MSS | 2026-03-15T05:35:57.492227+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_747389 | REC_0002628 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 25 | 12.4 | 65 | male | 1 | 11 | 5.6 | 3 | osimertinib 80 mg daily | 22.3 | false | MSS | 2026-03-15T05:35:57.492466+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_111983 | REC_0002629 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 22 | 9.6 | 86 | female | 2 | 21 | 6.7 | 3 | alectinib 600 mg BID | 7.3 | true | MSS | 2026-03-15T05:35:57.492694+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_300532 | REC_0002630 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 26 | 5 | 79 | female | 0 | 7 | 7.8 | 7 | pembrolizumab 200 mg q3w | 8.6 | true | MSS | 2026-03-15T05:35:57.492927+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_262639 | REC_0002631 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 22 | 18.2 | 58 | female | 0 | 11 | 7.7 | 2 | entrectinib 600 mg daily | 13.1 | false | MSI-H | 2026-03-15T05:35:57.493171+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_702580 | REC_0002632 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 29 | 5.6 | 62 | male | 1 | 0 | 3.6 | 1 | carboplatin + paclitaxel + pembrolizumab | 17.4 | true | MSS | 2026-03-15T05:35:57.493403+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_791091 | REC_0002633 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 23 | 15.2 | 66 | female | 0 | 15 | 4.9 | 7 | sotorasib 960 mg daily | 11.1 | false | MSI-H | 2026-03-15T05:35:57.493635+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_118389 | REC_0002634 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 15 | 24.8 | 73 | female | 2 | 8 | 3.8 | 1 | sotorasib 960 mg daily | 25.8 | true | MSS | 2026-03-15T05:35:57.493867+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_347248 | REC_0002635 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 9.9 | 54 | male | 0 | 14 | 6 | 7 | sotorasib 960 mg daily | 9.3 | true | MSS | 2026-03-15T05:35:57.494096+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_394702 | REC_0002636 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 21 | 12.3 | 56 | male | 1 | 13 | 4.4 | 1 | osimertinib 80 mg daily | 25.2 | false | MSS | 2026-03-15T05:35:57.494328+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_669955 | REC_0002637 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 17 | 14.8 | 64 | female | 0 | 20 | 7.3 | 2 | osimertinib 80 mg daily | 30.7 | false | MSI-H | 2026-03-15T05:35:57.494561+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_834647 | REC_0002638 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 25 | 14.6 | 58 | male | 0 | 18 | 7.5 | 6 | osimertinib 80 mg daily | 8.7 | false | MSI-H | 2026-03-15T05:35:57.494797+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_903941 | REC_0002639 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 26 | 8.3 | 82 | female | 2 | 7 | 5.4 | 4 | osimertinib 80 mg daily | 13.5 | true | MSS | 2026-03-15T05:35:57.495024+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_544377 | REC_0002640 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 28 | 9.5 | 66 | female | 0 | 16 | 4.5 | 1 | entrectinib 600 mg daily | 9.9 | false | MSS | 2026-03-15T05:35:57.495298+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_375666 | REC_0002641 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 30 | 7.7 | 67 | female | 1 | 68 | 5.8 | 6 | carboplatin + paclitaxel + pembrolizumab | 8.3 | false | MSS | 2026-03-15T05:35:57.495529+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_840465 | REC_0002642 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 32 | 12.6 | 55 | female | 0 | 22 | 3.8 | 4 | alectinib 600 mg BID | 6.8 | true | MSI-H | 2026-03-15T05:35:57.495764+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_309042 | REC_0002643 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 26 | 15.7 | 76 | female | 2 | 16 | 4.9 | 2 | sotorasib 960 mg daily | 29.8 | true | MSS | 2026-03-15T05:35:57.496001+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_968478 | REC_0002644 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 30 | 6.5 | 60 | female | 1 | 16 | 4.7 | 7 | osimertinib 80 mg daily | 7.2 | false | MSS | 2026-03-15T05:35:57.496396+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_776259 | REC_0002645 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 22 | 2.8 | 74 | male | 1 | 22 | 6.1 | 1 | carboplatin + paclitaxel + pembrolizumab | 19.9 | true | MSS | 2026-03-15T05:35:57.496638+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_773244 | REC_0002646 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 23 | 6.8 | 58 | female | 1 | 13 | 7.3 | 8 | pembrolizumab 200 mg q3w | 9.4 | false | MSS | 2026-03-15T05:35:57.496872+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_396673 | REC_0002647 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 27 | 6.3 | 54 | female | 0 | 54 | 5.4 | 5 | pembrolizumab 200 mg q3w | 6.1 | true | MSS | 2026-03-15T05:35:57.497107+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_366871 | REC_0002648 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 23 | 12.1 | 79 | male | 1 | 26 | 5 | 2 | osimertinib 80 mg daily | 21.7 | true | MSI-H | 2026-03-15T05:35:57.497345+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_181014 | REC_0002649 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 30 | 16.2 | 66 | female | 1 | 14 | 4.7 | 1 | osimertinib 80 mg daily | 14.3 | false | MSS | 2026-03-15T05:35:57.497577+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_499227 | REC_0002650 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 14 | 11.3 | 48 | female | 0 | 16 | 6.5 | 1 | entrectinib 600 mg daily | 16.1 | true | MSS | 2026-03-15T05:35:57.497812+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_263616 | REC_0002651 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 26 | 13.5 | 71 | female | 2 | 9 | 6.4 | 5 | pembrolizumab 200 mg q3w | 10.4 | false | MSS | 2026-03-15T05:35:57.498044+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_509422 | REC_0002652 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 21 | 11.3 | 61 | female | 1 | 14 | 5.6 | 7 | sotorasib 960 mg daily | 13.5 | true | MSS | 2026-03-15T05:35:57.498277+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_623403 | REC_0002653 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 27 | 18.8 | 61 | female | 1 | 18 | 7.4 | 5 | entrectinib 600 mg daily | 15.6 | false | MSI-H | 2026-03-15T05:35:57.498569+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_681346 | REC_0002654 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 22 | 14.6 | 68 | male | 1 | 5 | 7.9 | 2 | osimertinib 80 mg daily | 17.4 | false | MSS | 2026-03-15T05:35:57.498821+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_296835 | REC_0002655 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 20 | 16.8 | 65 | male | 0 | 13 | 6.7 | 1 | osimertinib 80 mg daily | 4.4 | false | MSI-H | 2026-03-15T05:35:57.499079+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_160337 | REC_0002656 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 24 | 3.1 | 60 | female | 1 | 75 | 6.3 | 0 | carboplatin + paclitaxel + pembrolizumab | 19.4 | true | MSS | 2026-03-15T05:35:57.499339+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_670063 | REC_0002657 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 24 | 8.7 | 69 | female | 1 | 14 | 8.2 | 2 | osimertinib 80 mg daily | 22.1 | true | MSS | 2026-03-15T05:35:57.499586+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_874900 | REC_0002658 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 25 | 8.1 | 60 | male | 1 | 17 | 7.7 | 4 | sotorasib 960 mg daily | 10.7 | true | MSS | 2026-03-15T05:35:57.499822+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_908508 | REC_0002659 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 25 | 18.6 | 61 | female | 1 | 16 | 3.5 | 2 | alectinib 600 mg BID | 26 | false | MSI-H | 2026-03-15T05:35:57.500065+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_689555 | REC_0002660 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 30 | 10.3 | 59 | female | 1 | 18 | 4.6 | 2 | alectinib 600 mg BID | 13.5 | false | MSI-H | 2026-03-15T05:35:57.500373+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_743382 | REC_0002661 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 29 | 8 | 79 | female | 2 | 18 | 5.8 | 5 | osimertinib 80 mg daily | 18.2 | true | MSS | 2026-03-15T05:35:57.500608+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_376233 | REC_0002662 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 25 | 11.9 | 69 | female | 0 | 11 | 5.5 | 3 | osimertinib 80 mg daily | 14.4 | false | MSS | 2026-03-15T05:35:57.500851+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_751593 | REC_0002663 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 24 | 11.7 | 66 | female | 0 | 10 | 5.1 | 4 | osimertinib 80 mg daily | 13.1 | true | MSI-H | 2026-03-15T05:35:57.501088+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_349231 | REC_0002664 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 27 | 9.9 | 58 | male | 1 | 15 | 5.4 | 7 | osimertinib 80 mg daily | 14.3 | false | MSS | 2026-03-15T05:35:57.501321+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_640496 | REC_0002665 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 30 | 12.9 | 62 | female | 0 | 4 | 6.2 | 1 | sotorasib 960 mg daily | 10.9 | false | MSI-H | 2026-03-15T05:35:57.501558+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_326745 | REC_0002666 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 25 | 4.4 | 81 | female | 1 | 36 | 5.3 | 1 | pembrolizumab 200 mg q3w | 21 | false | MSS | 2026-03-15T05:35:57.501894+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_568520 | REC_0002667 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 24 | 13.1 | 60 | female | 1 | 29 | 6.9 | 1 | alectinib 600 mg BID | 18.1 | true | MSI-H | 2026-03-15T05:35:57.502141+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_191889 | REC_0002668 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 30 | 15.8 | 66 | female | 0 | 19 | 4.2 | 5 | osimertinib 80 mg daily | 12.8 | false | MSS | 2026-03-15T05:35:57.502375+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_240724 | REC_0002669 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 25 | 11.3 | 73 | male | 1 | 10 | 5.6 | 1 | alectinib 600 mg BID | 26.8 | true | MSS | 2026-03-15T05:35:57.502613+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_551330 | REC_0002670 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 20 | 2.6 | 57 | male | 1 | 20 | 4.5 | 5 | pembrolizumab 200 mg q3w | 7.8 | true | MSS | 2026-03-15T05:35:57.502845+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_435786 | REC_0002671 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 27 | 7.6 | 82 | female | 1 | 0 | 3.8 | 2 | entrectinib 600 mg daily | 8.9 | true | MSS | 2026-03-15T05:35:57.503075+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_679392 | REC_0002672 | Non-small cell lung cancer | Adenocarcinoma | III | KRAS G12C | 18 | 18.5 | 79 | female | 2 | 9 | 4.7 | 0 | sotorasib 960 mg daily | 40.9 | true | MSI-H | 2026-03-15T05:35:57.503305+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_844765 | REC_0002673 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 19 | 7.1 | 65 | male | 1 | 10 | 6.1 | 2 | pembrolizumab 200 mg q3w | 27.4 | false | MSS | 2026-03-15T05:35:57.503585+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_774443 | REC_0002674 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 25 | 5.4 | 61 | male | 1 | 0 | 5.6 | 2 | osimertinib 80 mg daily | 23.6 | false | MSS | 2026-03-15T05:35:57.503832+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_602194 | REC_0002675 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 27 | 12.9 | 57 | female | 1 | 9 | 4.1 | 1 | entrectinib 600 mg daily | 13.5 | false | MSS | 2026-03-15T05:35:57.504127+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_637505 | REC_0002676 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 23 | 15.7 | 82 | female | 2 | 12 | 5 | 7 | osimertinib 80 mg daily | 17 | true | MSS | 2026-03-15T05:35:57.504387+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_182180 | REC_0002677 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 25 | 10.7 | 67 | female | 1 | 21 | 7.4 | 7 | pembrolizumab 200 mg q3w | 10.3 | true | MSS | 2026-03-15T05:35:57.504638+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_500126 | REC_0002678 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 18 | 6.2 | 61 | female | 1 | 26 | 6.1 | 6 | carboplatin + paclitaxel + pembrolizumab | 10.2 | false | MSS | 2026-03-15T05:35:57.504903+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_315781 | REC_0002679 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 20 | 11.4 | 72 | female | 3 | 22 | 6.4 | 4 | osimertinib 80 mg daily | 13.5 | false | MSI-H | 2026-03-15T05:35:57.505333+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_395006 | REC_0002680 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 32 | 17.2 | 60 | male | 1 | 9 | 5.1 | 6 | osimertinib 80 mg daily | 12.8 | false | MSS | 2026-03-15T05:35:57.505604+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_730827 | REC_0002681 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 21 | 16.6 | 72 | female | 2 | 18 | 3.9 | 2 | entrectinib 600 mg daily | 22.4 | false | MSI-H | 2026-03-15T05:35:57.505846+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_769211 | REC_0002682 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 30 | 7.2 | 63 | female | 0 | 64 | 4 | 5 | carboplatin + paclitaxel + pembrolizumab | 11.9 | false | MSS | 2026-03-15T05:35:57.506085+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_350297 | REC_0002683 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 26 | 16.4 | 70 | male | 3 | 8 | 4.4 | 8 | osimertinib 80 mg daily | 10.1 | true | MSI-H | 2026-03-15T05:35:57.506333+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_843491 | REC_0002684 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 22 | 7.3 | 81 | female | 2 | 26 | 5.5 | 1 | sotorasib 960 mg daily | 16.8 | false | MSS | 2026-03-15T05:35:57.506564+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_339808 | REC_0002685 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 23 | 15.3 | 55 | male | 1 | 17 | 8.1 | 2 | osimertinib 80 mg daily | 13 | false | MSS | 2026-03-15T05:35:57.506802+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_319178 | REC_0002686 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 27 | 13.6 | 66 | male | 1 | 21 | 4.7 | 5 | alectinib 600 mg BID | 10.2 | false | MSS | 2026-03-15T05:35:57.507037+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_885721 | REC_0002687 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 25 | 7.2 | 68 | male | 1 | 14 | 4.9 | 6 | pembrolizumab 200 mg q3w | 10.1 | true | MSS | 2026-03-15T05:35:57.507271+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_857885 | REC_0002688 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 18 | 14.1 | 60 | male | 0 | 15 | 4.7 | 1 | alectinib 600 mg BID | 24 | false | MSI-H | 2026-03-15T05:35:57.507509+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_178319 | REC_0002689 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 28 | 12.6 | 72 | female | 1 | 20 | 6 | 9 | osimertinib 80 mg daily | 10.1 | false | MSI-H | 2026-03-15T05:35:57.507742+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_764511 | REC_0002690 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 31 | 13.5 | 71 | male | 1 | 16 | 5.5 | 6 | osimertinib 80 mg daily | 13 | true | MSS | 2026-03-15T05:35:57.507977+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_441693 | REC_0002691 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 22 | 6.5 | 66 | male | 1 | 15 | 7.5 | 2 | alectinib 600 mg BID | 18.5 | true | MSS | 2026-03-15T05:35:57.508286+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_343721 | REC_0002692 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 28 | 9.1 | 61 | male | 1 | 15 | 6 | 5 | sotorasib 960 mg daily | 4.5 | true | MSS | 2026-03-15T05:35:57.508605+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_346168 | REC_0002693 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 32 | 12.9 | 76 | female | 1 | 14 | 4.3 | 3 | alectinib 600 mg BID | 12.5 | false | MSS | 2026-03-15T05:35:57.508845+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_940055 | REC_0002694 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 23 | 17.2 | 87 | male | 1 | 22 | 5.6 | 2 | osimertinib 80 mg daily | 16.1 | false | MSI-H | 2026-03-15T05:35:57.509085+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_589212 | REC_0002695 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 24 | 6.7 | 73 | female | 1 | 12 | 6.7 | 0 | osimertinib 80 mg daily | 14.8 | false | MSS | 2026-03-15T05:35:57.509316+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_789452 | REC_0002696 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 24 | 10.6 | 62 | male | 1 | 5 | 4.2 | 2 | pembrolizumab 200 mg q3w | 11.1 | false | MSI-H | 2026-03-15T05:35:57.509551+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_274787 | REC_0002697 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR L858R | 24 | 13.1 | 75 | female | 2 | 10 | 4.5 | 0 | osimertinib 80 mg daily | 33.1 | false | MSI-H | 2026-03-15T05:35:57.509783+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_847907 | REC_0002698 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 20 | 12.3 | 63 | male | 1 | 18 | 4.4 | 5 | alectinib 600 mg BID | 15.3 | false | MSS | 2026-03-15T05:35:57.510020+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_308029 | REC_0002699 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 23 | 8.1 | 70 | female | 3 | 11 | 4.5 | 2 | sotorasib 960 mg daily | 22.4 | true | MSS | 2026-03-15T05:35:57.510251+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_624571 | REC_0002700 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 19 | 5.6 | 79 | female | 0 | 60 | 6.2 | 2 | carboplatin + paclitaxel + pembrolizumab | 13.6 | false | MSS | 2026-03-15T05:35:57.510480+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.